DCAT Week '13
Date: 03/11/13 - 03/14/13
Founded in 1890, the Drug, Chemical & Associated Technologies Association, Inc. (DCAT) is a 501(c)6 non-profit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical and related industries. The Association provides services, programs and activities designed to support the business development objectives of its membership.
Click here to view the event website
DCAT Week '13 Presentation Information
Title: “Excipients: Innovation in Bioavailability Enhancement”
Program Description: Challenges in developing new, innovative drugs are ever increasing. It is estimated that up to 90% of drug candidates in development are poorly or almost completely insoluble in aqueous systems. The poor bioavailability of drugs has been identified as the single most important challenge in oral drug delivery. Improvements to bioavailability require that the product be stable while still remaining cost-effective. Innovators must develop technologies to enhance bioavailability early in the product development cycle to enable clinical and commercial success. However, drug candidates can be discarded due to poor bioavailability of the initial formulation without a thorough investigation of alternative preparations. This program will introduce concepts in bioavailability enhancement, provide insights into the current industry needs, look at the complex regulatory environment, and offer an outlook on the future of bioavailability enhancement.
Date: Tuesday, March 12, 2013
Time: 9:00 am - 11:30 am
Location: Astor Ballroom, InterContinental Hotel, NYC
- Dr. Keith Horspool, VP, Pharmaceutics, Boehringer Ingelheim
- Dr. Mansur Kahn, Director of the Division of Product Quality Research, U.S. Food and Drug Administration
- Dr. Nigel Langley, Head Technical Sales, Pharma Ingredients and Services, BASF Corporation
- Dr. Ralph Lipp, VP, Pharmaceutical Sciences R&D, Eli Lilly and Company
- David Lyon, Sr. VP, Research, Bend Research
- Kurt Nielsen, Chief Technology Officer, SVP of Innovation & Growth, Catalent Pharma Solutions
Following the presentations, the audience will have the opportunity to ask questions of our expert panel of speakers.
Here is the link to find your presentation on the brochure: http://www.dcat.org/Pages/progr_ShowProgram.aspx?IDProgram=103